skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8121

Biologics in the management of psoriasis

Review

(4775) Views  (1282) Full article downloads

Authors: Jennifer D Bahner, Lauren Y Cao, Neil J Korman

Published Date July 2009 Volume 2009:2 Pages 111 - 128
DOI: http://dx.doi.org/10.2147/CCID.S3629

Jennifer D Bahner1, Lauren Y Cao2, Neil J Korman1

1Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio, USA; 2Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Abstract: Psoriasis is a chronic inflammatory systemic disease for which there exist topical, ultraviolet, systemic, and biologic treatments. Biologic agents selectively interfere with the immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target tumor necrosis factor-alpha and have demonstrated efficacy in the treatment of psoriasis and psoriatic arthritis. Alefacept and efalizumab target T lymphocytes, are effective in the treatment of psoriasis, but are not approved for psoriatic arthritis. Finally, ustekinumab and ABT-874 target interleukin-12 and interleukin-23, and they have demonstrated efficacy in the treatment of psoriasis. The objective of this review is to present efficacy and safety data from randomized controlled trials of the biologic agents in the treatment of psoriasis.

Keywords: biologics, psoriasis, tumor necrosis factor, interleukin-12/23
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • American Acne and Rosacea Society

    The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.